Roche is aiming to make its human papillomavirus test a first-line diagnostic for cervical cancer, with a new FDA application for the Cobas HPV as a substitute for Pap tests.
Quest Diagnostics and Hologic inked a 5-year strategic deal calling for the companies to jointly develop and promote new women's health diagnostic products.
Roche took two steps forward and one step back on the Avastin front today, as investigators laid out a clear advantage in adding the therapy to chemo for cervical cancer while finding no survival advantage when adding it to first-line treatment of an aggressive form of brain cancer.
Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.
Merck and GlaxoSmithKline have some persuading to do. A growing share of U.S. parents say they won't vaccinate their daughters against human papillomavirus, which causes cervical cancer. And that leaves Merck's Gardasil and GSK's Cervarix with a shrinking market.
Could Avastin be on its way to another indication? On the heels of a broader approval for the drug in ovarian cancer in the EU, the U.S. National Institutes of Health has unveiled data showing Avastin helped patients with advanced cervical cancer live longer.
Relax, parents, vaccine researchers say. Merck's ($MRK) human papillomavirus vaccine has proven safe in another large study designed to gauge its side effects. Required by regulators in the U.S. and Europe, the study flagged a couple of reactions, but its lead author called the findings "very reassuring."
Low vaccination rates against human papillomavirus (HPV) in Europe have regulators there urging all girls to get vaccinated against the sexually transmitted virus.
The European Centre for Disease Prevention and Control (ECDC) now says all girls should be vaccinated against human papillomavirus, and it advises EU governments to push the shots. But the ECDC says vaccinating boys is "unlikely to be cost-effective."
Quest Diagnostics ($DGX) is rolling out a new test that spots molecular changes that heighten a woman's chance of developing cervical cancer.